Skip to main content

Table 1 Baseline characteristics of the patients (n = 61)

From: Association of culprit lesion plaque characteristics with flow restoration post-fibrinolysis in ST-segment elevation myocardial infarction: an intravascular ultrasound-virtual histology study

Variables TIMI flow 3 (n = 30) TIMI flow 1–2 (n = 31) p value
Age (years) 54.63 ± 8.98 57.10 ± 14.13 0.419
Male, n (%) 26 (86.7%) 26 (83.9%) 1.000
Hypertension, n (%) 5 (16.7%) 11 (35.5%) 0.095
Diabetes mellitus, n (%) 6 (20%) 7 (22.6%) 0.806
Smoking, n (%) 17 (56.7%) 12 (38.7%) 0.160
Family history of CAD, n (%) 3 (10%) 3 (9.7%) 1.000
BMI (kg/m2) 25.4 ± 4.17 25.10 ± 3.04 0.753
BSA (m2) 1.74 ± 0.13 1.74 ± 0.12 0.891
Symptom to thrombolysis time (hours) 4.77 ± 1.60 4.67 ± 1.47 0.809
Thrombolysis to PCI time (hours) 16.03 ± 1.37 15.71 ± 1.40 0.377
Hemoglobin (g/dL) 13.19 ± 1.85 13.31 ± 2.06 0.822
Creatinine (mg/dL) 1.1 ± 0.17 1.07 ± 0.18 0.485
Total cholesterol (mg/dL) 152.1 ± 52.85 139 ± 30.16 0.262
Triglycerides (mg/dL) 134.1 ± 47.18 119.2 ± 40.82 0.208
LDL-cholesterol (mg/dL) 100.8 ± 54.47 86.6 ± 33.42 0.247
HDL-cholesterol (mg/dL) 38.18 ± 9.05 38.84 ± 11.74 0.814
CK-MB (IU/l) 40 (36.25–53) 37 (31 − 97.75) 0.852
Ejection fraction, (%) 43.40 ± 4.28 40.25 ± 6.34 0.027
Thrombolysis, n (%) 0.656
Streptokinase 24 (80%) 22 (71%)
Reteplase 6 (20%) 8 (25.8%)
Tenecteplase 0 (0%) 1 (3.2%)
GP IIb-IIIa inhibitor use, n (%) 11 (36.7%) 10 (32.3%) 0.717
Medications at admission (%)
Antiplatelets (%) 2 (6.6%) 3 (9.6%) 1.000
Statins (%) 3 (10%) 4 (12.9%) 1.000
Beta blockers (%) 2 (6.6%) 5 (16.1%) 0.425
ACE I/ARBs (%) 4 (13.3%) 5 (16.1%) 1.000
OHAs (%) 3 (10%) 5 (16.1%) 0.707
Insulin (%) 2 (6.6%) 1 (3.2%) 0.612
  1. Data are presented as mean ± SD, median (interquartile range), or n (%)
  2. CAD coronary artery disease, BMI body mass index, BSA body surface area, PCI percutaneous coronary intervention, LDL low-density lipoprotein, HDL high-density lipoprotein, CK-MB creatine kinase-myocardial band (IU/l), ACE I angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers, OHA oral hypoglycemic agents